Preliminary Analysis of Changes in Logistics Processes to Assess the Impact of a Pandemic

The research literature in computer science provides a way of understanding the growing capabilities of information technology (IT) and anticipating their future effect on work and skills. This chapter reviews a set of recent computer science articles to identify the IT capabilities that have been demonstrated in research settings. These capabilities are compared to information on occupational ability requirements to identify occupations that are potentially vulnerable to displacement as demonstrated IT capabilities are refined and applied over the next couple decades. The chapter’s preliminary analysis suggests that occupations representing 82 percent of current employment will be potentially vulnerable to displacement by IT in the near future. More rigorous versions of the chapter’s preliminary analysis should be carried out once or twice each decade to track the further development of IT capabilities and regularly update our understanding of their likely consequences for work and skills.

Download Full-text

The Impact of a Confusion of Social Objectives on Public Housing: A Preliminary Analysis

Marriage and Family Living ◽

10.2307/348304 ◽

1955 ◽

Vol 17 (2) ◽

pp. 103

Author(s):

H. Warren Dunham ◽

Nathan D. Grundstein

Keyword(s):

Public Housing ◽

Preliminary Analysis ◽

The Impact

Download Full-text

Comparison of International Source-Term Codes

MRS Proceedings ◽

10.1557/proc-333-769 ◽

1993 ◽

Vol 333 ◽

Author(s):

W. Zhou ◽

M. J. Apted ◽

P. Robinson

Keyword(s):

Nuclear Waste ◽

Preliminary Analysis ◽

Source Term ◽

Near Field ◽

Different Types ◽

Solution Methods ◽

Initial Comparison ◽

Models Comparison ◽

The Impact ◽

Transport Factors

ABSTRACTSource-term codes to predict the release of radionuclides from nuclear waste packages have been developed and implemented worldwide. A survey and initial comparison of the attributes and capabilities of 13 international source-term codes was recently completed. This preliminary analysis focused on comparison of transport factors/processes and solution methods. This initial comparison is a necessary first step in a properly-conceived, systematic benchmarking of source-term codes. Advantages of such a comparison include assurance of the mathematical correctness of implemented models, comparison and quantification of variances introduced by different types of simplifications, and identification and quantification of the impact of near-field processes.

Download Full-text

What Is the Impact of Survivorship Visits?: Preliminary Analysis From a NCI-Designated Cancer Center Radiation Oncology Program

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2014.05.2088 ◽

2014 ◽

Vol 90 (1) ◽

pp. S715

Author(s):

A. Leatherwood ◽

O.V. Sostin ◽

Y. Chen ◽

C.R. Thomas

Keyword(s):

Radiation Oncology ◽

Preliminary Analysis ◽

Cancer Center ◽

The Impact

Download Full-text

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Blood ◽

10.1182/blood.v108.11.13.13 ◽

2006 ◽

Vol 108 (11) ◽

pp. 13-13 ◽

Cited By ~ 42

Author(s):

Alan K. Burnett ◽

William J. Kell ◽

Anthony H. Goldstone ◽

Donald Milligan ◽

Ann Hunter ◽

...

Keyword(s):

Induction Chemotherapy ◽

Preliminary Analysis ◽

De Novo ◽

Remission Rate ◽

Pilot Trial ◽

Disease Free Survival ◽

Gemtuzumab Ozogamicin ◽

Significant Difference ◽

The Impact

Abstract The MRC AML15 Trial is primarily for patients with any form of AML who are under 60 years. One of the questions addressed was whether the addition of the immunoconjugate, Gemtuzumab Ozogamicin (GO) to induction (course 1) and/or consolidation (course 3) is beneficial. In induction patients are randomised to receive either DA (Daunorubicin/Ara-C) or ADE (Ara-C/Daunorubicin/Etoposide) or FLAG-Ida (Fludarabine/Ara-C/Idarubicin/G-CSF) and in consolidation either MACE (Amsacrine/Etoposide) or HD Ara-C (3.0g/m2 or 1.5g/m2 per dose). Our prior pilot trial had shown that GO 3mgs/m2 could be safely added to day 1 of each of these treatments (Kell et al Blood102, 4277–4283). Here we report the preliminary results of the effect of combining GO with induction chemotherapy. This randomisation achieved its recruitment target and was closed on 30 June 2006. All other comparisons in the trial, including GO in consolidation, remain open. Patients: A total of 1115 patients were randomised between July 2002 and June 2006. The median age was 49 (range 0–71) years: 53% of patients were male: 92% (n=1027) had de novo disease: 95% had WHO performance score of <2: 43% received DA, 43% FLAG-Ida, and 14% ADE. (Recruitment to ADE+GO opened in June 2005). Patients with WBC > 30 x 109/l and LFT’s > normal were initially excluded but admitted from March 2004. APL patients were not eligible for entry. 15% of patients with data had favourable 71% intermediate, and 14% adverse cytogenetics. Over 83% were CD33 positive. Results: The overall remission rate was 85% with no differences between the arms for GO vs no GO in CR (85% vs 85%) induction death (8% vs 7%) or resistant disease (7% vs 8%). There was a modest increase in mucositis on the GO arm in course 1 only (p=0.04) and increased AST and Alt toxicity in C1 (p=.002; p=.03) but no difference in bilirubin grades. GO patients used more platelets (19 vs 14; p<0.0001), but not red cells, and had more days on IV antibiotics (20.6 vs 18.6 p=0.001). The haemopoietic recovery and days in hospital were similar. With a median follow-up of 15 months (range 0–45), there is no significant difference in deaths in CR (GO vs no GO): 36 vs 45 (HR 0.75; CI.49–1.16 p=0.2), but relapse was reduced: 37% vs 52% at 3 years (HR 0.70 (0.52–0.92) p=0.01) resulting in an improved DFS: 51% vs 40% at 3 years (HR 0.72 (0.56–0.91) p=0.008). There is so far no significant difference in OS (53% vs 46% at 3 years; HR 0.91(0.73–1.14) p=0.4). Conclusion: This preliminary analysis of 1115 randomised patients indicates that the addition of GO to induction chemotherapy can reduce the relapse risk without adding significant extra toxicity and this has significantly improved the DFS in the GO arm. Longer follow up is required to determine the impact on survival.

Download Full-text